By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084



Company News
First Human Patient Treated In Phase 1b Study Of Advaxis, Inc.'s ADXS-HER2 In HER2 Expressing Solid Tumors 9/28/2015 7:55:01 AM
Advaxis, Inc.'s Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival In Patients With Persistent/Recurrent Metastatic Cervical Cancer 9/18/2015 6:34:15 AM
Advaxis, Inc. Release: FDA Awards Grant For Phase 2 Study Of Axalimogene Filolisbac (ADXS-HPV) In HPV-Associated Head And Neck Cancer 9/14/2015 7:31:09 AM
1} Accepts Medical Visionary Award From The Farrah Fawcett Foundation For Collaborative Research In HPV-Associated Anal Cancer 9/10/2015 7:41:09 AM
Advaxis, Inc. To Present At The 2015 Wells Fargo Securities Healthcare Conference 9/2/2015 7:36:19 AM
Phase II Study Of Advaxis, Inc.'s Axalimogene Filolisbac (ADXS-HPV) In Cervical Cancer To Be Presented At 2015 AGOS Annual Meeting 8/31/2015 7:24:06 AM
Advaxis, Inc. Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management 8/26/2015 7:10:11 AM
Advaxis, Inc. And MedImmune (AZN) Commence Enrollment In Phase I/II Study Of Axalimogene Filolisbac (ADXS-HPV) In Combination With Durvalumab (MEDI4736) For The Treatment Of HPV-Associated Cancers 8/20/2015 7:59:57 AM
Advaxis, Inc. Appoints Tom Ridge, America's First Secretary Of Homeland Security And 43rd Governor Of Pennsylvania, To Board Of Directors 8/13/2015 7:51:13 AM
Advaxis, Inc.'s ADXS-PSA Awarded Research Grants From The Prostate Cancer Foundation And The Movember Foundation 8/5/2015 7:22:20 AM